1
|
Nakchbandi IA, Mitnick MA, Masiukiewicz US, Sun BH, Insogna KL. IL-6 negatively regulates IL-11 production in vitro and in vivo. Endocrinology 2001; 142:3850-6. [PMID: 11517162 DOI: 10.1210/endo.142.9.8368] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
IL-6 and IL-11 are two cytokines that increase osteoclast formation and augment bone resorption. PTH stimulates the production of both cytokines by human osteoblast-like cells. Circulating levels of IL-6 are elevated in patients with states of PTH excess and correlate strongly to markers of bone resorption. In contrast, serum levels of IL-11 were significantly reduced in patients with primary hyperparathyroidism compared with values in euparathyroid controls. Further, after successful parathyroid adenomectomy, circulating levels of IL-6 fell, whereas IL-11 levels increased. Five-day infusions of human PTH-(1--84) in rodents resulted in a significant decline in mean circulating levels of IL-11, whereas IL-6 levels significantly increased. Pretreatment of cells and mice with neutralizing serum to IL-6 enhanced PTH-induced IL-11 production compared with the effect of pretreatment with nonimmune sera. These data indicate that IL-6 negatively regulates IL-11 production in vivo and in vitro. Analysis of steady state mRNA levels in SaOS-2 cells indicated that this effect is posttranscriptional. As both IL-6 and IL-11 stimulate osteoclast formation, down-regulation of IL-11 by IL-6 may help modulate the resorptive response to PTH.
Collapse
Affiliation(s)
- I A Nakchbandi
- Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06520-8020, USA
| | | | | | | | | |
Collapse
|
4
|
Elson GCA, Graber P, Losberger C, Herren S, Gretener D, Menoud LN, Wells TNC, Kosco-Vilbois MH, Gauchat JF. Cytokine-Like Factor-1, a Novel Soluble Protein, Shares Homology with Members of the Cytokine Type I Receptor Family. THE JOURNAL OF IMMUNOLOGY 1998. [DOI: 10.4049/jimmunol.161.3.1371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Abstract
In this report we describe the identification, cloning, and expression pattern of human cytokine-like factor 1 (hCLF-1) and the identification and cloning of its murine homologue. They were identified from expressed sequence tags using amino acid sequences from conserved regions of the cytokine type I receptor family. Human CLF-1 and murine CLF-1 shared 96% amino acid identity and significant homology with many cytokine type I receptors. CLF-1 is a secreted protein, suggesting that it is either a soluble subunit within a cytokine receptor complex, like the soluble form of the IL-6R α-chain, or a subunit of a multimeric cytokine, e.g., IL-12 p40. The highest levels of hCLF-1 mRNA were observed in lymph node, spleen, thymus, appendix, placenta, stomach, bone marrow, and fetal lung, with constitutive expression of CLF-1 mRNA detected in a human kidney fibroblastic cell line. In fibroblast primary cell cultures, CLF-1 mRNA was up-regulated by TNF-α, IL-6, and IFN-γ. Western blot analysis of recombinant forms of hCLF-1 showed that the protein has the tendency to form covalently linked di- and tetramers. These results suggest that CLF-1 is a novel soluble cytokine receptor subunit or part of a novel cytokine complex, possibly playing a regulatory role in the immune system and during fetal development.
Collapse
Affiliation(s)
- Greg C. A. Elson
- Department of Immunology, Geneva Biomedical Research Institute, Glaxo Wellcome Research and Development, Plan-les-Ouates, Switzerland
| | - Pierre Graber
- Department of Immunology, Geneva Biomedical Research Institute, Glaxo Wellcome Research and Development, Plan-les-Ouates, Switzerland
| | - Christophe Losberger
- Department of Immunology, Geneva Biomedical Research Institute, Glaxo Wellcome Research and Development, Plan-les-Ouates, Switzerland
| | - Suzanne Herren
- Department of Immunology, Geneva Biomedical Research Institute, Glaxo Wellcome Research and Development, Plan-les-Ouates, Switzerland
| | - Denise Gretener
- Department of Immunology, Geneva Biomedical Research Institute, Glaxo Wellcome Research and Development, Plan-les-Ouates, Switzerland
| | - Laurent N. Menoud
- Department of Immunology, Geneva Biomedical Research Institute, Glaxo Wellcome Research and Development, Plan-les-Ouates, Switzerland
| | - Timothy N. C. Wells
- Department of Immunology, Geneva Biomedical Research Institute, Glaxo Wellcome Research and Development, Plan-les-Ouates, Switzerland
| | - Marie H. Kosco-Vilbois
- Department of Immunology, Geneva Biomedical Research Institute, Glaxo Wellcome Research and Development, Plan-les-Ouates, Switzerland
| | - Jean-François Gauchat
- Department of Immunology, Geneva Biomedical Research Institute, Glaxo Wellcome Research and Development, Plan-les-Ouates, Switzerland
| |
Collapse
|
5
|
Taga T. The signal transducer gp130 is shared by interleukin-6 family of haematopoietic and neurotrophic cytokines. Ann Med 1997; 29:63-72. [PMID: 9073325 DOI: 10.3109/07853899708998744] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Receptors for many of the cytokines functioning in the haematopoietic system belong to the class I cytokine receptor family. In most cases these receptors share common signal transducing receptor components in the same family, which explains the functional redundancy of haematopoietic cytokines. Interleukin-6 and related cytokines, interleukin-11, leukaemia inhibitory factor, oncostatin M, ciliary neurotrophic factor and cardiotrophin-1, are all pleiotrophic, from the haematopoietic to the nervous system, and exhibit overlapping biological activities. Receptors for these cytokines fall into the class I cytokine receptor family. Functional receptor complexes for the interleukin-6 family of cytokines share a membrane glycoprotein 130 (gp130) as a critical component for signal transduction. In these receptor complexes, gp130 and ligand-specific chains possess no intrinsic tyrosine kinase domain but are associated with cytoplasmic tyrosine kinases. Ligand stimulation triggers homo- or heterodimerization of gp130, leading to activation of the associated cytoplasmic tyrosine kinases and subsequent modification of transcription factors. This paper reviews the recent progress in the study of gp130 and the background information from biomedical and biochemical viewpoints.
Collapse
Affiliation(s)
- T Taga
- Department of Molecular Cell Biology, Medical Research Institute, Tokyo Medical and Dental University, Japan
| |
Collapse
|
6
|
Abstract
Receptors for most interleukins and cytokines that regulate immune and hematopoietic systems belong to the class I cytokine receptor family. These molecules form multichain receptor complexes in order to exhibit high-affinity binding to, and mediate biological functions of, their respective cytokines. In most cases, these functional receptor complexes share common signal transducing receptor components that are also in the class I cytokine receptor family, i.e. gp130, common beta, and common gamma molecules. Interleukin-6 and related cytokines, interleukin-11, leukemia inhibitory factor, oncostatin M, ciliary neurotrophic factor, and cardiotrophin-1 are all pleiotropic and exhibit overlapping biological functions. Functional receptor complexes for this interleukin-6 family of cytokines share gp130 as a component critical for signal transduction. Unlike cytokines sharing common beta and common gamma chains that mainly function in hematopoietic and lymphoid cell systems, the interleukin-6 family of cytokines function extensively outside these systems as well, e.g. from the cardiovascular to the nervous system, owing to ubiquitously expressed gp130. Stimulation of cells with the interleukin-6 family of cytokines triggers homo- or hetero-dimerization of gp130. Although gp130 and its dimer partners possess no intrinsic tyrosine kinase domain, the dimerization of gp130 leads to activation of associated cytoplasmic tyrosine kinases and subsequent modification of transcription factors. This paper reviews recent progress in the study of the interleukin-6 family of cytokines and gp130.
Collapse
Affiliation(s)
- T Taga
- Institute for Molecular and Cellular Biology, Osaka University, Japan
| | | |
Collapse
|
7
|
Bamborough P, Grant GH, Hedgecock CJ, West SP, Richards WG. A computer model of the interleukin-4/receptor complex. Proteins 1993; 17:11-9. [PMID: 8234241 DOI: 10.1002/prot.340170105] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Interleukin-4 is a member of the cytokine family, a group of related messenger proteins which collectively help to moderate and control the immune response. It is believed that the folding topology of the beta-sheets of the interleukin-4 receptor (IL4R) is the same as that seen in the crystal structure of CD4. Although the sequence identity is low, homology modeling techniques have been used to model the IL4R structure from CD4. Refinement by molecular dynamics leads to a suggested structure which has been docked to interleukin-4 (IL4). Several residues of apparent importance for binding are identified.
Collapse
Affiliation(s)
- P Bamborough
- Oxford Centre for Molecular Science, Oxford University, United Kingdom
| | | | | | | | | |
Collapse
|
8
|
Abstract
Cytokines act via receptor-mediated pathways to influence the regulation of both immune and non-immune cells. This review will discuss some of the most important developments over the past year which have contributed to the elucidation of the mechanisms of cell activation by these molecules.
Collapse
Affiliation(s)
- H P Benton
- Department of Zoology, University of California, Davis, 95616
| |
Collapse
|
9
|
Yoshimura A, Longmore G, Lodish HF. Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity. Nature 1990; 348:647-9. [PMID: 2174515 DOI: 10.1038/348647a0] [Citation(s) in RCA: 247] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The receptors for erythropoietin and other cytokines constitute a new superfamily. They have no tyrosine-kinase or other enzyme motif and their signal-transducing mechanism is unclear. Here we describe two classes of activating mutations in the erythropoietin receptor (EPOR). A single point mutation in the exoplasmic domain enables it to induce hormone-independent cell growth and tumorigenesis after expression in nontumorigenic, interleukin-3-dependent haematopoietic cells. A C-terminal truncation in the cytoplasmic domain of the EPOR renders the receptor hyperresponsive to erythropoietin, but is insufficient to induce hormone-independent growth or tumorigenicity. The activating point mutation retards intracellular transport and turnover of the receptor. These alterations in metabolism and tumorigenicity caused by the EPOR with activating point mutations are similar to those observed in erythropoietin-independent activation of the wild type EPOR by association with gp55, the Friend spleen focus-forming virus glycoprotein.
Collapse
Affiliation(s)
- A Yoshimura
- Whitehead Institute for Biomedical Research, Cambridge, Massachusetts
| | | | | |
Collapse
|